Amarin vs Puma Biotechnology
Puma Biotechnology reported revenue of $228 million in fiscal 2025, about the same as Amarin's $214 million in fiscal 2025. Amarin's revenue fell 6.5% in its latest year, and Puma Biotechnology's fell 0.9%. Amarin had an operating margin of -23.5%, against 16.3% at Puma Biotechnology.
Side by side
| Amarin | Puma Biotechnology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $214M | $228M |
| Revenue growth | −6.5% | −0.9% |
| Revenue growth a year, last 5 years | −19.0% | 0.3% |
| Gross margin | 56.6% | 74.5% |
| Operating margin | −23.5% | 16.3% |
| Net margin | −18.2% | 13.6% |
| Free cash flow | — | $42M |
| Free cash flow margin | — | 18.3% |
| Return on capital | — | 48.2% |
| Net debt to EBITDA | — | −1.4x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.0% | 3.2% |
| Last close | $11.26 | $7.12 |
| P/E at the last close | — | 15.5× |
| Insider trades, last 12 months | — | sold $2.0 million |
| Piotroski F-score | — | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AmarinPuma Biotechnology
Operating margin
Percent of revenue
AmarinPuma Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AmarinPuma Biotechnology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amarin and Puma Biotechnology pages.